Omniose was founded in 2016 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has been awarded $11.2 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.
Omniose announced an expansion of the team in April 2022 with the addition of Timothy Cooke as CEO and Roman Fleck as Chairperson. Both of these highly experienced executives are based in the Boston area. The company also announced the formation of a Scientific Advisory Board with co-founder Mario Feldman and Steven Projan, who brings deep industry experience in infectious disease drug and vaccine development.